Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
4(33%)

Phase Distribution

Ph phase_4
6
50%
Ph phase_3
2
17%
Ph phase_2
2
17%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

2

Mid Stage

8

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
6(54.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(6)
Terminated(4)
Other(2)

Detailed Status

Completed6
Terminated4
unknown2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (9.1%)
Phase 22 (18.2%)
Phase 32 (18.2%)
Phase 46 (54.5%)

Trials by Status

unknown217%
terminated433%
completed650%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_4

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

NCT03463317
completedphase_3

Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

NCT02933697
completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

NCT03563937
terminatedphase_2

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF

NCT02256683
completedphase_1

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

NCT01849666
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03463317Phase 4

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed
NCT02933697Phase 3

Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)

Completed
NCT03563937

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon

Completed
NCT02256683Phase 2

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF

Terminated
NCT01849666Phase 1

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Completed
NCT02872649Phase 2

Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)

Terminated
NCT02591225Phase 4

Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

Unknown
NCT01352702Phase 4

Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

Terminated
NCT00528671Phase 4

Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications

Terminated
NCT01339819Phase 4

Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

Completed
NCT00586287Phase 4

Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon

Completed
NCT00895505Phase 3

D-Dimer Guided Oral Anticoagulant Treatment (OAT)

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12